Citigroup Maintains Neutral on Biogen, Lowers Price Target to $190

Benzinga Newsdesk www.benzinga.com Negative 76.5%

Neg 76.5% Neu 0% Pos 0%

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $215 to $190.